ANTI-LEUKEMIC EFFECT OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF ALLOGENEIC MARROW GRAFTS
ANTI-LEUKEMIC EFFECT OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF ALLOGENEIC MARROW GRAFTS
复制标题
DOI：
10.1056/nejm197905103001902
复制
发表时间：
1979-01-01
影响因子：
158.5
通讯作者：
STORB, R
中科院分区：
文献类型：
--
作者：
WEIDEN, PL;FLOURNOY, N;STORB, R
确定同种异体骨髓移植是否与移植物vs.对46例同卵双生（同基因）骨髓受体、117例HLA同卵同胞（异基因）骨髓受体无或极轻微移植物抗宿主病和79例异基因骨髓受体中的中度至重度或慢性疾病的白血病效应、白血病复发与移植物抗宿主病之间的关系进行了检查。有移植物抗宿主病的异基因骨髓受者的相对复发率比无移植物抗宿主病的受者低2.5倍（P < 0.01）。这种明显的抗白血病作用在淋巴细胞白血病患者中比在非淋巴细胞白血病患者中更明显，在复发期间而不是在缓解期间接受移植的患者中，在移植后的前130天内最明显。所有患者的生存率相当，因为移植物抗宿主病患者复发白血病的概率较低，但其他死亡原因的概率较高。
To determine whether allogenic bone marrow transplantation is associated with a graft-vs.-leukemia effect, the relation between relapse of leukemia and graft vs. host disease in 46 recipients of identical-twin (syngeneic) marrow, 117 recipients of HLA-identical-sibling (allogeneic) marrow with no or minimal graft vs. host disease and 79 recipients of allogeneic marrow with moderate to severe or chronic disease was examined. The relative relapse rate was 2.5 times less in allogeneic-marrow recipients with graft vs. host disease than in recipients without it (P < 0.01). This apparent antileukemic effect was more marked in patients with lymphoblastic than nonlymphoblastic leukemia, in those who received transplants during relapse rather than during remission and was most evident during the first 130 days after transplantation. Survival of all patients was comparable since the lesser probability of recurrent leukemia in patients with graft vs. host disease was offset by a greater probability of other causes of death.